READING, Pa., Dec. 1, 2022 /PRNewswire/ — PharmaForce International (PFI) recently published a benchmarking report covering the digital marketing trends and expenditures of key Oncology and Immunology companies. The report provides a strategic overview of the best practices, as well as each individual company’s approach to the evolving digital marketing landscape. Several note-worthy trends were captured within the report. One trend, in particular, is the progression of the digital marketing footprint over the past 20 years.
At the beginning of the COVID-19 pandemic, many pharma companies in the United States had to rely almost entirely on digital channels to connect with healthcare professionals (HCPs). This large use of digital channels during the pandemic further validated the significant influence it has in the overall success of a brand. Now, companies have gone back to utilizing some face-to-face interactions, but still dedicate a much larger percentage of marketing approaches to digital methods. Digital footprints are expected to only expand moving forward, but also diversify in how pharma companies market to both patients and HCPs.
Allison Keylor, Director of the United States Business Unit at PFI, states that “Digital marketing is not a new concept for most pharmaceutical companies, as many of these companies have always had digital aspects, such as product websites, in place. However, what is innovative about digital marketing now is the direct effect it has on brand strategy.”
“Website traffic, clicks, and social media play such an essential role in connecting brands to patients and HCPs in today’s market. Connecting via digital mediums has become more tactical in recent years, with close watch on ROI and having the ability to carefully measure investment versus return as a top priority among pharmaceutical marketers. Looking ahead, digital concepts will continue to impact strategic decisions and the approach pharmaceutical companies make to connect with patients in new and meaningful ways” say Keylor.
For more information on the report mentioned above, please contact Joyce Wedemeyer at Joyce.Wedemeyer@pharmaforceintl.com or by phone at 610-370-2906.
PharmaForce International (PFI) is a competitive intelligence firm with over two decades of experience in the pharmaceutical and biotech industries. PFI has become the market leader in commercial operations benchmarking and competitive intelligence.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmaforce-international-benchmarking-report-captures-the-digital-marketing-trends-of-key-oncology-and-immunology-companies-301691910.html
SOURCE PharmaForce International
We all pay taxes. So why not get some of that money back?
Tesla (NASDAQ: TSLA) had a rough time on the stock market in 2022, and the pressure keeps building. Competitors are getting better, consumers have less money to spend on vehicles, and Elon Musk is distracted by Twitter.
The U.S. stock market, as measured by the S&P 500 Index (SPX) has struggled this week overall, during what is typically a seasonally bullish period. Typically, SPX rallies a little over 1% during that time period. The SPX chart itself has resistance at 3900-3940, after the breakdown below 3900 in mid-December.
Democrats released six years of Donald Trump’s income-tax returns on Friday, providing further insight into the former president’s tax situation. Trump and his wife, Melania, paid $0 in income taxes for 2020, according to a report released late Tuesday by the congressional Joint Committee on Taxation. The nonpartisan committee’s findings also raised several red flags related to the filings, namely Trump’s carryover losses, loans to his children that may or may not also be considered taxable gifts, and deduction-related tax write-offs.
These two semiconductor investors are back to discuss what Nvidia experts predict artificial intelligence can change in 2023.
First, develop a plan (some might call it a budget), said Robert Gilliland, managing director and senior wealth adviser at Concenture Wealth Management. Take into consideration every single possible expense you anticipate after your husband dies, and account for inflation as well. You can break these expenses down into the short term, such as one to five years, the intermediate term, which would be the six- to 10-year span, and the long term, or beyond 10 years.
You may not even realize its presence is lurking around every corner.
In 2017, business magnate Warren Buffett did something that’s somewhat unusual for him. He poured hundreds of millions of dollars into a real estate investment. Buffett has been dismissive of real estate investing in the past. He’s called it a “lousy investment” in part because real estate can be expensive to maintain. Real estate also often requires “sweat equity” or the physical effort needed to upgrade properties or simply keep them from falling into disrepair. Yet in 2017, Berkshire Hathaway
Berkshire Hathaway's portfolio can be a useful resource for finding quality companies at a good value.
Tech stocks took a beating in 2022. Semiconductor giant Intel (NASDAQ: INTC) and telecom company AT&T (NYSE: T) each face their fair share of challenges in 2023 and beyond, but dividend investors would be remiss to ignore these high-yield tech stocks. For much of the past two years, shares of chip giant Intel have been slumping under the leadership of CEO Pat Gelsinger.
Li Auto and Nio reported record December sales while XPeng rebounded. BYD, which cited Covid disruptions, is on tap.
Let's talk about the popular General Electric Company ( NYSE:GE ). The company's shares received a lot of attention…
There were few places for investors to hide in this year’s bloodbath, but those exposed to the tech-heavy Nasdaq Composite index undoubtedly had it the worst.
The federal government will allow you to save nearly 10% more for retirement in 2023. Only 14% of participants saved the maximum amount in 2020. Not everyone needs that kind of money put away for retirement.
This disruptive company has been mauled by 2022's bear market, but it's setting the stage for a massive rebound.
These stocks fell significantly in 2022. But analysts expect that huge rebounds could be on the way in the new year.
Apple (NASDAQ: AAPL) has benefited from robust consumer demand and hopes that easing supply chain constraints will boost the tech giant's prospects. *Stock prices used were the afternoon prices of Dec.
Palantir (NYSE: PLTR) hopes to accelerate revenue growth in 2022 as businesses look to analyze their data for insights. *Stock prices used were the afternoon prices of Dec. 29, 2022. The video was published on Dec.
A trust can hold many different assets, including your individual retirement account (IRA). Doing so can have benefits for you and your heirs, but it's important to structure the trust properly. We'll discuss how a trust works and what you … Continue reading → The post Can Your IRA be Placed in a Trust? appeared first on SmartAsset Blog.
These are high-conviction stocks for the Oracle of Omaha but they're trading at knocked-down prices.
